Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 May 21;14(19):2990-4.
doi: 10.3748/wjg.14.2990.

c-Met targeted therapy of cholangiocarcinoma

Matei-P Socoteanu  1 , Frank Mott, Gianfranco Alpini, Arthur-E Frankel
Affiliations
Review

c-Met targeted therapy of cholangiocarcinoma

Matei-P Socoteanu et al. World J Gastroenterol. .

Abstract

Cholangiocarcinoma continues to be a challenging disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase II trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
c-Met immunohistochemistry performed on: A: Normal liver; B: Cholangiocarcinoma; C: Early stage cholangiocarcinoma; D: Bile duct hyperplasia reproduced from Fazari (19) with permission.
Figure 2
Figure 2
Schema of c-Met signaling pathways.
See this image and copyright information in PMC

References

    1. Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, Chen P, Busuttil RW. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 2001;7:1023–1033. - PubMed
    1. Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, Fung JJ, Starzl TE. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg. 1998;187:358–364. - PMC - PubMed
    1. Goldstein RM, Stone M, Tillery GW, Senzer N, Levy M, Husberg BS, Gonwa T, Klintmalm G. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg. 1993;166:768–771; discussion 771-772. - PubMed
    1. Becker NS, Rodriguez JA, Barshes NR, O'Mahony CA, Goss JA, Aloia TA. Outcomes Analysis for 280 Patients with Cholangiocarcinoma Treated with Liver Transplantation Over an 18-year Period. J Gastrointest Surg. 2008;12:117–122. - PubMed
    1. Thongprasert S. The role of chemotherapy in cholangio-carcinoma. Ann Oncol. 2005;16 Suppl 2:ii93–ii96. - PubMed

MeSH terms